vaccine

Who will be first in line for a COVID-19 vaccine

Dr. Anthony Fauci says a possible coronavirus vaccine entering a phase three trial has been promising.

The U.S. government will pay drugmakers Sanofi and GlaxoSmithKline up to $2.1 billion to develop and deliver 100 million doses of their potential coronavirus vaccine, the companies announced Friday. More than half of the $1.5 billion will be used to support further development of the vaccine, including clinical trials. The rest will be for manufacturing and delivery of the 100 million doses, the...

As COVID-19 continues to take lives and shut-down the global economy, there is more pressure than ever to develop a vaccine as quickly as possible. On May 15, 2020, President Trump unveiled “Operation Warp Speed,” an ambitious plan to develop a a vaccine against COVID-19 by the end of the year.  While this timeline isn’t impossible, many experts agree it…

Morgon Fraser is all-in on becoming one of 500 locals taking part in Moderna’s Phase 3 COVID-19 vaccine trials at the UC San Diego School of Medicine.

The head of the Chinese Center for Disease Control and Prevention says he has been injected with an experimental coronavirus vaccine in an attempt to persuade the public to follow suit when one is approved

President Donald Trump’s handling of the coronavirus pandemic put his political fate in grave jeopardy

Tens of thousands of volunteers will take part in the study, with results being reported as soon as November.

The world’s biggest COVID-19 vaccine test got underway Monday with the first of 30,000 planned volunteers

Early data shows a vaccine under development by Oxford University and AstraZeneca triggers antibodies and the production of virus-fighting T-cells.

Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot

Western governments are accusing hackers believed to be part of the Russian intelligence services of trying to steal information about a coronavirus vaccine

Moderna’s shares soared after the company said its potential vaccine to prevent Covid-19 produced a “robust” immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine. Moderna’s stock rose more than 16% in after-hours trading on the news.  All 45 patients produced…

Politicians and public health leaders have publicly committed to equitably sharing any coronavirus vaccine that works, but the top global initiative to make that happen may allow rich countries to reinforce their own stockpiles while making fewer doses available for poor ones

When precious vats of COVID-19 vaccine are finally ready, the ability to jab the lifesaving solution into the arms of Americans will require hundreds of millions of injections

Six months after COVID-19 started spreading around the globe, desperation rather than information is still driving many decisions about how to treat the disease

Peter Pitts, the former FDA Associate Commissioner, said industry, academia and government are working together to make an effective coronavirus vaccine available by early 2021. But the rollout is expected to be complicated, with more than one vaccine likely available and questions about which groups should be prioritized to get the vaccine first.

U.S. health officials say the flu vaccine did a disappointing job last winter, and officials worry it might be a bad sign for the fall

Several major players in the global race for a coronavirus vaccine took steps to move their research forward this week. Pharmaceutical companies developing potential vaccines, including Moderna and Johnson & Johnson, announced start times for various phases of clinical trials in humans. In addition, a U.S. Army lab announced the selection of a lead vaccine candidate, along with two...

Moderna Inc. on Thursday unveiled large-scale, expedited plans to begin the final stage of testing on its COVID-19 vaccine.  The Cambridge-based biotech company plans to enroll 30,000 people in the U.S. in the Phase 3 test of its COVID-19 vaccine, according to a press release. The company also plans to begin testing in July — months sooner than the fall…